Doctor who founded Ohio Wildlife Center dead at 63

Columbus Dispatch - 15 hours ago
Through the years, its services...

What the Recent Run-Up in Ebola Stocks Taught Investors

Equities.com - 3 days ago
TLSR: I think we're seeing a...

Heartbeats: Hospital to hold dedication

MyCentralJersey.com - 4 days ago
Saint Peter's University...

Nevada Sunrise Agreement on the Roulette Gold Property in Eastern Nevada

GlobeNewswire (press release) - 4 days ago
Nevada Sunrise has recently...

TSX Mining Stock News: Nevada Sunrise (TSXV: NEV) Agreement on the ...

InvestorIdeas.com (press release) - 4 days ago
Nevada Sunrise has recently...

play online roulette games

Musalman Times - 2 hours ago
En als klap op de vuurpijl heeft...

Georgia Lawmakers Reveal New Medical Marijuana Bill for 2015

The Daily Chronic - 1 week ago
“If what we're going to do...

100 things to know about Medicare and Medicaid

Becker's Hospital Review - 2 weeks ago
President Nixon expanded Medicare...

Terumo BCT pleit voor uitbreiding Mirasol-behandeling

Netherlands Corporate News (persbericht) - 2 days ago
Vanwege zorgen om de verspreiding...

Ann Arbor area business briefs: University Bank and Retirement Income Solutions

MLive.com - 4 weeks ago
University of Michigan experts in...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.